https://orcid.org/0000-0003-0502-3829
References
- Griffin MP, Yuan Y, Takas T, et al. Single-dose nirsevimab for prevention of RSV in preterm infants. N Engl J Med. 2020 Jul 30;383(5):415–425.
- Mulangu S, Dodd LE, Davey RT, et al. A randomized, controlled trial of ebola virus disease therapeutics. N Engl J Med. 2019 Dec 12;381(24):2293–2303.
- Dougan M, Nirula A, Azizad M, et al. Bamlanivimab plus etesevimab in mild or moderate COVID-19. N Engl J Med. 2021 Oct 7;385(15):1382–1392.
- Emergency Use Authorization FDA. https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization.
- Corti D, Purcell LA, Snell G, et al. Tackling COVID-19 with neutralizing monoclonal antibodies. Cell. 2021;184(12):3086–3108.
- Baum A, Fulton BO, Wloga E, et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science (New York, NY). 2020 Aug 21;369(6506):1014–1018.
- Shi R, Shan C, Duan X, et al. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature. 2020;584(7819):120–124.
- Barnes CO, Jette CA, Abernathy ME, et al. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature. 2020;588(7839):682–687.
- McCallum M, Walls AC, Sprouse KR, et al. Molecular basis of immune evasion by the delta and kappa SARS-CoV-2 variants. Science. 2021 Dec 24;374(6575):1621–1626.
- Starr TN, Greaney AJ, Dingens AS, et al. Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016. Cell Reports Medicine. 2021 Apr 20;2(4):100255.